Business Wire

ERYTECH Collaborates with Fox Chase Cancer Center to Advance Its Platform in the Field of Rare Metabolic Disorders

Del

Regulatory News:

ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Fox Chase Cancer Center (FCCC) to advance the pre-clinical development of the Company’s erymethionase program for homocystinuria, a rare and severe metabolic disorder of methionine metabolism. The collaboration will leverage FCCC’s world-class expertise to generate in vivo proof-of-concept data with erymethionase in a homocystinuria animal model.

Classical homocystinuria is a rare, inherited genetic disease caused by a deficiency in the enzyme Cystathionine Beta-Synthase (CBS), which is critical for methionine metabolism. Patients are unable to fully metabolize the amino acid methionine, an essential amino acid found in food, which leads to the accumulation of homocysteine and methionine in the blood and urine. High levels of these amino acids are directly linked to morbidity and mortality, often at a young age. Symptoms include severe intellectual disability, eye lens dislocation, thromboembolism, osteoporosis, and seizures.

The collaboration between ERYTECH and FCCC aims to demonstrate the potential of ERYTECH’s erymethionase to lower homocysteine and methionine in the homocystinuria mouse model (CBS-deficient mice) developed by Professor Warren Kruger’s lab at FCCC. Erymethionase is a methionine gamma-lyase (MGL, methioninase) enzyme encapsulated in red blood cells using ERYTECH’s proprietary ERYCAPS technology platform to provide effective, long-acting therapeutic activity with reduced toxicity. In addition to the homocystinuria program, ERYTECH is developing erymethionase as a product candidate targeting cancer metabolism. New preclinical data supporting the potential role of erymethionase as a treatment approach against a broad range of cancers that rely on methionine metabolism will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 1 – 5, 2017 in Washington, D.C.

Pr. Warren Kruger, PhD, Fox Chase Cancer Center, commented, “ERYTECH’s approach with erymethionase has significant potential in this disease setting because it can reduce the levels of both homocysteine and methionine in blood plasma which is critical in restoring the metabolic balance in individuals with classical homocystinuria. We look forward to working with ERYTECH to advance this preclinical program to determine its potential as a therapeutic option for homocystinuria patients.”

Dr. Alexander Scheer, PhD, Chief Scientific Officer of ERYTECH, added, “Classical homocystinuria remains a very challenging genetic disorder that the unique mechanism of action of erymethionase has the potential to directly and meaningfully impact. We are very pleased to enter this collaboration with FCCC and look forward to working closely with Dr. Kruger on this program as we accelerate the development of our technology platform to include highly specialized and rare conditions beyond oncology. This collaboration emphasizes ERYTECH’s overarching strategy to develop novel, safer therapies to address high unmet medical needs.

About Fox Chase Cancer Center: www.foxchase.org

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach.
For more information, call 1-888-FOX CHASE or (1-888-369-2427).

About ERYTECH: www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. ERYTECH plans to pursue regulatory approvals for its lead product candidate, eryaspase, also known under the trade name GRASPA®, having achieved positive efficacy and safety results from its completed Phase 2/3 pivotal clinical trial in Europe in children and adults with relapsed or refractory ALL. ERYTECH also has an ongoing Phase 1 clinical trial of eryaspase in the United States in adults with newly diagnosed ALL, and a Phase 2b clinical trial in Europe in elderly patients with newly diagnosed AML, each in combination with chemotherapy. ERYTECH believes that eryaspase also has the potential as a treatment approach in solid tumors and is conducting a Phase 2 clinical trial in Europe in patients with metastatic pancreatic cancer.

In addition to eryaspase, ERYTECH is developing two other product candidates that focus on using encapsulated enzymes to induce tumor starvation. The company is leveraging the ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme therapies beyond oncology (ERYZYME), such as the development of erymethionase in homocystinuria.

ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the U.S. under an ADR level 1 program (OTC, ticker EYRYY).

Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development plans, business and regulatory strategy, and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on ERYTECH’s website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

Contact information

ERYTECH
Gil Beyen
Chairman and CEO
or
Eric Soyer
CFO and COO
+33 4 78 74 44 38
investors@erytech.com
or
The Ruth Group
Investor relations
Lee Roth, +1 646 536 7012
lroth@theruthgroup.com
or
Media relations
Kirsten Thomas, +1 508 280 6592
kthomas@theruthgroup.com
or
NewCap
Julien Perez

Investor relations
or
Nicolas Merigeau
Media relations
+33 1 44 71 98 52
erytech@newcap.eu

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Rimini Street Announces $140 Million Refinancing18.6.2018 21:30Pressemelding

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced it has entered into a binding agreement with a syndicate of investors, including a fourth round of equity participation by Rimini Street’s largest shareholder, Adams Street Partners, to refinance its current credit facility with the issuance of $140 million of Series A convertible preferred stock and 2.9 million shares of common stock. Closing is subject to a shareholder vote and certain other customary closing conditions. Holders of a majority of the Company’s common stock have agreed to vote in favor of the transaction, and the Company expects the transaction to close in the third quarter of 2018. The transaction is expected to unlock more than $95 million of cash flow over the next three years as compared to the current credit facility. The transaction extends the expected financing matu

Quanergy to Feature ‘Qortex for Security’ at IFSEC18.6.2018 20:30Pressemelding

Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, today announced that it will be demonstrating its LiDAR-based security system at multiple booths during IFSEC International, Europe’s premier security trade show. This year’s conference will take place June 19-21, 2018 in London, UK. Quanergy’s security system, Qortex for Security, is an innovative, LiDAR-based 3D perimeter fencing and intrusion detection system. An integrated hardware and software platform, this intelligent security solution combines Quanergy’s M8 mechanical LiDAR sensor with its proprietary Qortex perception software. The platform is fully integrated into existing VMS (Video Management System) and PSIM (Physical Security Information Management) infrastructure and offers surveillance automation with real-time people detection, tracking and classification. “Qortex for Security is a prime example of the many benefits that LiDAR hardware and sof

Inside Secure to Provide Secure Provisioning Solutions to NationalChip18.6.2018 15:35Pressemelding

Regulatory News: Inside Secure (Paris:INSD), at the heart of security solutions for mobile and connected devices, announced it entered into an agreement with Hangzhou NationalChip Science and Technology Co., Ltd, a leading innovator and developer of SoCs (system-on-chip), to use Inside Secure’s Secure Provisioning Solution to build robust security into its products during the chip manufacturing process. Secure provisioning is recognized as a crucial, foundational security building block across diverse markets including automotive, entertainment, IoT, mobile and TV. Securing devices or end products can be worthless if their identities and cryptographic keys have been compromised during manufacturing. Widely-publicized attacks have targeted provisioning because they can affect large numbers of devices and are difficult to detect. Chipmakers and device manufacturers see the potential for new revenue sources by offering secure provisioning to their customers, leveraging technology solution

Citi Private Bank Congratulates Fernando Alonso on the 24 Hours of Le Mans Win18.6.2018 14:01Pressemelding

Citi Private Bank ardently congratulates Fernando Alonso for his impressive win at The 24 Hours of Le Mans this past weekend. Mr. Alonso, who is also a two time Formula One World Champion, most recently competed and won the Six Hours of Spa-Francorchamps in May. In January he debuted at the Rolex 24 at Daytona. Previously he participated in the Indianapolis 500 in May of 2017. He was sponsored by Citi Private Bank for all four races. Alongside the Indianapolis 500 and the Monaco Grand Prix, Le Mans makes up one third of ‘the Triple Crown of Motor Racing’. Having already won Monaco twice, Mr. Alonso is on a quest to become only the second driver in history to complete the Triple Crown. “Fernando drove one the most thrilling races at Le Mans that I have ever seen. His stunning night time drive will likely go down as one of the greatest victories in motorsport’s history,” said Peter Clive Charrington, Global Head of Citi Private Bank. “Fernando possesses an unrelenting drive toward excell

Inteva Products Receives Top Innovation Award for Revolutionary Stitching Process18.6.2018 13:31Pressemelding

Inteva Products, LLC, a leading global Tier One automotive supplier of engineered components and systems, received the top prize in the 2018 Innovation Awards presented by the European Association of Automotive Suppliers (CLEPA) at The Hague, Netherlands, on June 13. Inteva was recognized for its new real-time scanning process for the robotic stitching of automotive interiors. This innovative technology will be used on instrument panels for the 2019 Chevrolet Silverado and GMC Sierra pickup trucks. The new process enables “live” scanning and immediate adjustments to the program path of robotic stitching equipment as a component is being stitched. This approach aligns leading-edge advances in the use of lasers in automotive manufacturing with Inteva’s unique robotic stitching technologies. The advancement reduces the average cycle time of a stitched surface by approximately 20-30%. The 2018 CLEPA Innovation Awards, organized in cooperation with Deloitte, celebrate automotive excellence

P&G Advances Systemic Change for Gender Equality in Advertising at 2018 Cannes Lions Festival of Creativity18.6.2018 12:25Pressemelding

The Procter & Gamble Company (NYSE: PG) today advanced its commitment to gender equality through a series of new actions, commitments and partnerships to increase diversity throughout the creative supply chain, leading to more accurate and positive portrayals of women in advertising and media, and driving growth and social good. Women and girls are inaccurately or negatively portrayed in 29 percent of ads and media programs*, and women continue to be underrepresented behind the camera: only 32 percent of Chief Marketing Officers, 33 percent of Chief Creative Officers and a mere 10 percent of Commercial Directors are women. These issues persist despite evidence that gender-equal ads perform 10 percent higher in trust and 26 percent higher in sales growth*. To address these issues, P&G has called for an aspiration to achieve 100% accurate and positive portrayals of women in advertising and media, supported by equal representation of women and men in the creative supply chain. P&G is lead